$10.00—Stale · unknown old
NASDAQ • Last print unknown ago
$10.00—Stale · unknown old
Apollo Endosurgery, Inc. specializes in minimally invasive surgical devices, particularly in the bariatric and gastrointestinal markets. Its competitive position is bolstered by proprietary technologies such as the OverStitch and the EndoBariatric platform, which cater to a growing demand for weight loss and digestive health solutions in North America and Europe.
Apollo generates revenue primarily through the sale of its innovative surgical devices, which are priced at a premium due to their unique capabilities. The company benefits from high gross margins of 55.2%, driven by its proprietary technology and the growing trend towards minimally invasive procedures.
Adoption rates of OverStitch and EndoBariatric systems in hospitals
Regulatory approvals for new products
Partnerships with healthcare providers and distributors
Trends in obesity rates and related healthcare spending
Regulatory changes affecting medical device approvals
Technological advancements by competitors that could render current products obsolete
Emerging competitors in the minimally invasive surgery space
Price competition from established medical device manufacturers
High debt-to-equity ratio of 1.75 may limit financial flexibility
Negative net margins indicate potential liquidity issues if losses continue
moderate - The demand for surgical devices is somewhat correlated with economic conditions, as healthcare spending typically rises during economic expansions.
Higher interest rates could increase Apollo's financing costs, impacting its ability to invest in R&D and marketing. However, the direct impact on demand for surgical devices is limited.
minimal - Apollo's operations are not heavily reliant on credit markets, but high debt levels may constrain future financing options.
growth - Investors are likely attracted by the company's potential for rapid revenue growth in a niche market.
high - The stock has shown significant price volatility, with a 1-year return of 97.6% reflecting market sentiment shifts.